Make a Gift
Read Our Blog
TOKYO—(BUSINESS WIRE)—Otsuka Pharmaceutical Co., Ltd. announced today that the European Commission has granted marketing authorisation for JINARC® (tolvaptan) for the treatment of ADPKD in adults who have chronic kidney disease (CKD) stage one to three at initiation of treatment with evidence of rapidly progressing disease. In receiving this marketing authorisation, tolvaptan becomes the first pharmaceutical therapy to be licensed in Europe for the treatment of the underlying pathophysiology of ADPKD.
New Orleans Saintsations Kriste Lewis, along with others impacted by PKD, helps create awareness in this promotional video. Please help spread the word to people who may not know about this disease by sharing this video.
2000 Daniel Island Drive, Charleston SC 29492
Phone: 800.443.9441 | Fax: firstname.lastname@example.org
©2015, PKD Foundation ·The PKD Foundation is a 501 (c)(3), 509 (a)(1) public charity.